|Bid||0.5361 x 100|
|Ask||0.5497 x 100|
|Day's Range||0.5200 - 0.5700|
|52 Week Range||0.2600 - 2.1500|
|PE Ratio (TTM)||-0.86|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The The Woodlands, Texas-based company said it had a loss of 8 cents per share. The biopharmaceutical company posted revenue of $7,000 in the period. The company's shares closed at 35 cents. A year ago, ...
Lack of revenues in Repros Therapeutics' (RPRX) product portfolio could be a concern. But the company's most advanced pipeline candidates -- enclomiphene and Proellex -- might better its results in Q2.
Repros Therapeutics Inc. (RPRX) announced that its pipeline candidate Proellex which is being evaluated for uterine fibroids will remain on partial clinical hold.
On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 22 cents. The biopharmaceutical company posted revenue of $7,000 in the period. In the final minutes of trading on Tuesday, ...
Repros Therapeutics Inc. (RPRX) is expected to report first-quarter 2017 results this month. Let's see how things are shaping up for this quarter.
Repros Therapeutics (RPRX) announced that the FDA will continue to maintain partial clinical hold on its pipeline candidate Proellex for uterine fibroids indication as the agency internally reviews data related to the effect of the same on the liver
On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 16 cents. The biopharmaceutical company posted revenue of $5,000 in the period. For the year, the company reported that ...
Repros (RPRX) announced that it has requested a meeting with the FDA to discuss requirements for phase III development of Proellex.
Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap […]
The S&P 500 and Dow are pushing new highs as 2016 comes to a close. While the post-election tailwind has been incredibly strong, there are still companies holding back this rally.
Repros Therapeutics Inc. (RPRX) reported a loss of 17 cents per share in the third quarter of 2016, significantly narrower than the year-ago loss of 27 cents.